投资机构Raymond James宣布,将生物制药公司Dianthus Therapeutics Inc.(DNTH)的股票评级从“跑赢大盘”上调至“强力买入”。与此同时,该机构将其目标股价从原先的63美元显著调高至123美元,显示出对该公司未来增长前景的强烈信心。
投资机构Raymond James宣布,将生物制药公司Dianthus Therapeutics Inc.(DNTH)的股票评级从“跑赢大盘”上调至“强力买入”。与此同时,该机构将其目标股价从原先的63美元显著调高至123美元,显示出对该公司未来增长前景的强烈信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.